---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000041"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:53:54.427720+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences appoints Yvonne Li Interim CFO; CEO Lu named interim PFO

## Summary
- Timothy Lu, CEO/President, becomes interim principal financial & accounting officer effective May 4, 2024.
- Yvonne Li appointed Interim CFO effective May 4, 2024; will become principal financial & accounting officer after Q1 10-Q filing.
- Li consulting agreement: $350/hour, max aggregate payment of $370,000.

## SEC filing metadata
- accession: 0001854270-24-000041
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/0001854270-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/snti-20240426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000041
- JSON: https://secwatch.observer/filing/0001854270-24-000041.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000041.txt

## Key facts
- Executive change
  Yvonne Li was appointed as Interim Chief Financial Officer at Senti Biosciences, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/0001854270-24-000041-index.htm
- Executive change
  Timothy Lu was appointed as interim principal financial officer and principal accounting officer at Senti Biosciences, Inc..
  - Action: appointed
  - Role: interim principal financial officer and principal accounting officer
  source text: Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000041/0001854270-24-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.